- Jennifer Flora: Center of Excellence for Photobiomodulation, Shepherd University, Shepherdstown, West Virginia, USA.
- Kelly Watson Huffer: Center of Excellence for Photobiomodulation, Shepherd University, Shepherdstown, West Virginia, USA.
The opioid crisis, a declared national health emergency, has prompted the exploration of innovative treatments to address the pervasive issues of opioid cravings and associated depression. This pilot cohort study investigated the efficacy of transcranial Photobiomodulation (tPBM) therapy using the SunPowerLED helmet to alleviate these symptoms in individuals undergoing treatment for opioid addiction at a rehabilitation center in West Virginia. Employing a quasi-experimental design, this study enrolled participants into two groups: one receiving tPBM therapy alongside standard care and a control group receiving standard care alone. The helmet features include the following: total wavelength = 810 nm, total irradiance = 0.06 W/cm (60 m W/cm), and total fluence = 172.8J/cm. The results of the Wilcoxon signed-rank tests for within-group analysis and Mann-Whitney U tests for between-group comparisons revealed statistically significant reductions in the intensity (W = 7.36 = 0.012), time (W = 6.50, = 0.015), frequency (W = 6.50, = 0.010), and total scores of opioid cravings (W = 7.50, = 0.009), as well as improvements in depression symptoms (W= 8.00, = 0.005) within the PBM group compared to the non-PBM group. These findings suggest that transcranial PBM therapy could be a promising noninvasive intervention for reducing opioid cravings and depressive symptoms in individuals with opioid use disorder, warranting further investigation through larger randomized controlled trials.